drugset / Trial / NCT00284817
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
\- Assess the safety and tolerance of a weekly MEDI522 regimen in patients with irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.
Timeline
- Start
- 2001-07
- Primary completion
- 2005-01
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | etaracizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | etaracizumab | Monoclonal antibody | 3 mg/kg | Intravenous |